『Overall survival of super‑elderly (85 years or older) advanced non‑small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first‑line gefitinib therapy: a single‑institute retrospective study』(J Cancer Res Clin Oncol 2020, published Aug 6) まとめ 85歳以上の超高齢非小細胞肺…